



Pegtibatinase: An Enzyme Replacement Therapy in Development for Classical Homocystinuria

Sunday, 19 March 2023, 5:30-7:00pm MDT
SIMD Satellite Symposium
Hyatt Regency Salt Lake City
Alta Conference Room, Level 3



Traverse Therapeutics looks forward to welcoming you to a satellite symposium at the Society for Inherited Metabolic Disorders (SIMD) 2023 44th Annual Meeting.

We hope you can join our renowned experts **Drs Harvey Levy, Janet Thomas, Tomas Majtan,** and **Can Ficioglu** to discuss current and future management of classical homocystinuria.

Agenda

Welcome and Introduction

Harvey Levy

Overview of Classical Homocystinuria

Janet Thomas

Preclinical Insights Into Pegtibatinase Enzyme Replacement Therapy

Tomas Majtan

Pegtibatinase Clinical Data From COMPOSE (Phase 1/2 Trial)

Can Ficioglu

Your Questions Answered: Panel Discussion

Harvey Levy and Faculty

This meeting is open to all registered delegates at the SIMD 2023 congress.

Food and refreshments will be provided



Scan for more information about Traverse Therapeutics

Speakers

Harvey Levy, MD (Chair)

Senior Physician in Medicine,
Division of Genetics and Genomics,
Boston Children's Hospital

Professor of Pediatrics,
Harvard Medical School, USA



Janet Thomas, MD

Professor, Pediatrics-Clinical Genetics
and Metabolism,

University of Colorado
School of Medicine, USA



Tomas Majtan, PharmD, PhD

Assistant Professor,
Department of Pharmacology,
Faculty of Science and Medicine,
University of Fribourg, Switzerland



Can Ficioglu, MD, PhD

Professor of Pediatrics,
University of Pennsylvania

Director, Newborn Screening and Lysosomal
Storage Disease Programs,
Children's Hospital of Philadelphia, USA

